Memory-Loss Breakthrough: Mayo Clinic Discovers New Form of Memory Loss that Resembles Alzheimer’s but Progresses Differently!

Rochester, Minnesota – Scientists at the Mayo Clinic in Minnesota have uncovered a new form of memory loss called Limbic-predominant amnestic neurodegenerative syndrome (LANS). This syndrome affects the limbic system of the brain, responsible for regulating emotions and behavior. Unlike Alzheimer’s disease, LANS progresses at a slower rate and carries a more positive prognosis, according to a press release from the Mayo Clinic. The researchers analyzed data from over 200 patients from various sources to …

Read more

Anorexia Study Reveals Secret to Treating Eating Disorders: Acetylcholine Deficiency Reversed by Alzheimer’s Drug

Montreal, CANADA – Anorexia nervosa, a debilitating eating disorder, may be tied to a decreased release of a specific brain chemical, according to a recent animal study. Researchers found that male mice with a rare genetic variant associated with eating disorders and substance use disorders showed a deficiency in the neurotransmitter acetylcholine in the striatum, a brain region linked to learned behaviors, cravings, and reward. The study, led by neuroscientist Mathieu Favier and colleagues at …

Read more

Mother’s Side Alzheimer’s History Increases Inherited Disease Risk, Study Finds

Boston, MA – A recent study conducted by researchers at Mass General Brigham revealed a surprising link between maternal history of Alzheimer’s disease and an increased risk of inherited disease compared to a paternal history. The study analyzed 4,400 adults aged 65 to 85 without cognitive decline symptoms, but with amyloid present in brain scans, a protein associated with Alzheimer’s disease. Individuals with higher levels of amyloid were more likely to have mothers with Alzheimer’s …

Read more

FDA Approval for Revolutionary Alzheimer’s Drug – Kisunla Clears Way for Breakthrough Treatment

Indianapolis, Indiana – The Food and Drug Administration gave the green light on Tuesday to a new Alzheimer’s treatment called donanemab, marking the third addition to a novel class of drugs designed to slow the brain’s decline in patients grappling with the early stages of the disease. Named Kisunla by Eli Lilly, the drug’s approval comes after facing numerous setbacks and delays in bringing the experimental treatment to the market, despite promising results from clinical …

Read more

Breakthrough: FDA Approves Alzheimer’s Drug Kisunla for Slowing Disease Progression

INDIANAPOLIS, Ind. – The Food and Drug Administration granted approval on Tuesday to a highly anticipated Alzheimer’s drug called Kisunla, manufactured by Eli Lilly. This approval comes after a delay in March to further assess the drug’s safety and effectiveness. The drug was greenlit by the FDA following a panel of independent experts unanimously endorsing it in May. Kisunla, the brand name for donanemab, is one of the few Alzheimer’s treatments that actually modifies the …

Read more

Alzheimer’s Breakthrough: FDA Approves New Drug from Eli Lilly to Slow Cognitive Decline

Indianapolis, Indiana – The Food and Drug Administration has recently given approval for a new Alzheimer’s drug developed by Eli Lilly, offering hope to those affected by the disease. Named Kisunla, the drug has shown promise in slowing down the decline in memory and cognitive abilities in individuals through clinical trials. The medication, which is a monoclonal antibody infusion administered every four weeks, has been cleared for use in adults with mild cognitive impairment or …

Read more

Alzheimer’s Researcher Fraud Scandal Shocks Industry – Click to Uncover the Truth!

Los Angeles, CA – An Alzheimer’s researcher, known for his work in developing potential treatments for the disease, has been charged with fraud in a major scandal that has rocked the medical community. This news has not only sent shockwaves through the scientific world but has also caused stocks of the company associated with the researcher to plummet. The researcher, who has been a key figure in the study of Alzheimer’s disease for many years, …

Read more

Alzheimer’s Drug Researcher Indicted for Fraud: Shocking Allegations Revealed by Federal Grand Jury

New York City – A neuroscientist from the City University of New York, whose research contributed to the development of an Alzheimer’s drug candidate, faces allegations of fraud. The indictment centers around accusations of falsifying research images and data to secure government grants, a matter of growing concern in the scientific community. Hoau-Yan Wang, the medical professor in question, collaborated with Cassava Sciences on the investigation of simufilam, an Alzheimer’s drug candidate. Wang received substantial …

Read more

Scientist Indicted for Fabricating Research Data Linked to Alzheimer’s Drug Conspiracy – Shocking Details Inside!

New York, USA – A neuroscientist in New York faces fraud charges related to the alleged fabrication of research data, impacting the development of an Alzheimer’s drug candidate. The scientist, Hoau-Yan Wang, has come under scrutiny for his involvement in securing grants through manipulated images and data, as reported by the Justice Department on Friday. Wang, a medical professor at the City University of New York, collaborated with Cassava Sciences on the investigation of the …

Read more